Briavix identifies concentration, aging, dilution, payment-term and margin exposure before you enter a factoring or working-capital discussion.
Margin-at-Risk
82%
of receivables assessed as financing-eligible
18% concentrated in two counterparties
The figure above, and the portfolio and scenario figures below, are illustrative sample data — not a real client case.
Factoring or invoice discounting converts receivables into cash, but concentration, dilution and payment-term risk sitting inside that portfolio remain. Understanding them first changes what you ask for — and how a lender or factor prices it.
Eligible receivables, dilution history, concentration limits and covenant-ready reporting.
How much of the portfolio is genuinely eligible, and what margin or cash risk remains after financing.
Eligible receivables
82%
Of total AR
At-risk receivables
18%
Concentration flagged
Overdue 60+ days
AED 410K
2 counterparties
Open disputes
3
Under review
Stress scenarios applied to current gross margin.
Pre-financing
17.6%
Current portfolio, no facility in place.
Post-financing, base case
19.8%
Facility drawn against eligible receivables.
Post-financing, concentration event
26.4%
A top counterparty payment slips.
Invoices, AR aging and customer concentration data.
Extraction and analyst validation of eligible vs. at-risk receivables.
Margin and cash impact before and after financing assumptions.
A partner-ready pack you can bring into the financing conversation.
A redacted sample Margin-at-Risk Board Report, prepared the same way yours will be.
Understand your receivables portfolio before you enter a financing conversation.
Request a Pre-Finance DiagnosticUse Briavix to qualify and prepare client cases before underwriting.
Discuss a Partner Pilot